The perils of clinical trials

Kidney International

Volumn 85, Issue 4, 2014, Pages 745-747

  Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLUCOSIDE;

ANTIDIABETIC ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG RESEARCH; URINARY EXCRETION; BLOOD; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; FEMALE; MALE;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLUCOSIDES; HUMANS; MALE;

EID: 84897408865     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.406     Document Type: Note

References (10)

1. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009; 31: 2608-2617.
2. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; 9: 529-550.
3. Committees CPG. Canadian Diabetes Association Clinical Practice Guidelines. Can J Diabetes 2013; 37(Suppl 1): S1-S212.
4. Kohan DE, Fioretto P, Tang W et al. Long-Term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-971.
5. Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Taal MW, Chertow GM, Marsden PA et al. (eds). Brenner and Rector's The Kidney, 9th edn. Elsevier: Philadelphia, PA, 2012, pp 252-292.
6. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One [online] 2012; 7: E30555.
7. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
8. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
9. Barnett AH, Mithal A, Manassie J et al. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and renal impairment (RI). Diabetes 2013; 62(Suppl 1): 1104-P.
10. Thomson SC, Rieg T. Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75-R83.